Research & Development
Prostate Cancer: Page 3
Genetic risk score may reduce invasive prostate biopsies
In research published Thursday in the British Journal of Cancer, the U.K.-based researchers calculated genetic risk for prostate cancer by leveraging more than 250 known genetic variants that are commonly linked to the disease. These genetic variants were all combined to form a single genetic risk score that could then be used to assess an individual's genetic risk of developing prostate cancer.
August 18, 2022
Deep Bio integrates DeepDx AI algorithm into Halo AP platform
DeepDx Prostate detects prostate cancer in core needle biopsies and grades their severity based on the Gleason scoring system, according to the vendor.
August 9, 2022
MDxHealth buys Exact Sciences’ prostate cancer business
Under the terms of an asset purchase agreement, MDxHealth paid $25 million in cash; $5 million will be settled through the delivery of 691,171 American depositary shares.
August 2, 2022
miR Scientific develops molecular prostate cancer test
miR Sentinel is a molecular test that analyzes small noncoding RNA using a biostatistical algorithm. It assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men under the age of 45 who are at risk for prostate cancer.
July 13, 2022
Clinics begin adopting Genetic Technologies risk test
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
Nanostics reports study results for prostate cancer test
The test's machine-learning algorithm combines data from two biological biomarkers and three clinical biomarkers to generate a risk score for clinically significant prostate cancer.
June 29, 2022
Indica gets CE-IVD Mark for prostate cancer screening tool
The algorithm helps pathologists identify and grade prostate cancer from core needle biopsy samples. It was developed by researchers at the University of Cologne in Germany and was trained with more than 870,000 digital scans of prostate cancer subtypes as well as healthy tissue.
May 22, 2022
Artemis signs $250M deal for liquid biopsy tests with Datar
The contract gives Artemis DNA the exclusivity to commercialize and distribute the liquid biopsy tests Trucheck Pragma and Cancertrack in the U.S. and Vietnam. Trucheck Pragma is a noninvasive blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; Cancertrack is a cancer monitoring test that allows patients to evaluate response/resistance during treatment and monitor recurrence of cancer.
May 15, 2022
Paige gets nod in Europe for prostate biomarker suite
The AI software is designed to detect the presence of four prostate cancer biomarkers on digitized tissue images stained with hematoxylin and eosin (H&E).
May 11, 2022
Cleveland Diagnostics' IsoPSA gets NCCN prostate cancer listing
The guidelines now suggest use of IsoPSA to categorize probability of high-grade prostate cancer (i.e., Gleason score equal to or greater than 3+4, and group grade of 2 or higher) before a first biopsy or after a negative biopsy, the company said.
May 10, 2022
Accounting for genetic factors may improve PSA testing
Presenter Linda Kachuri, PhD, of the University of California, San Francisco, and colleagues investigated whether particular genetic factors could cause variations in PSA levels that are not due to cancer, and whether accounting for these could improve PSA testing. They conducted a study that included 95,000 men with diagnosed prostate cancer from cohorts in the U.S., the U.K., and Sweden and identified 128 PSA-associated variants they used to "build a polygenic score for PSA levels."
April 10, 2022
MiR Scientific, Leonie Hill to partner on prostate cancer test
The test uses a single urine sample to identify prostate cancer and classify disease severity, according to miR Scientific. Its technology is based on analyzing small noncoding RNAs taken from urinary exosomes; clinical studies have shown that it can find and categorize clinically significant prostate cancer with more than 90% accuracy, the company said.
March 27, 2022
Page 3 of 7